Podcasts about series alzheimer

In my latest podcast, I talk to Professor David Smith, Emeritus Professor of Pharmacology at the University of Oxford, about a decade of ground-breaking research showing that brain shrinkage can be reduced by as much as 70 per cent with the right nutrients and why it's vital to screen early for cognitive function and homocysteine to identify those at risk and reverse that risk. To find out more visit https://www.patrickholford.com/topic/alzheimers-and-dementia

William Mobley, MD, PhD shares the latest research on preventing Alzheimer's disease in people with Down syndrome. He looks at the genetics and progression of both conditions and shares potential therapies to reduce APP expression that leads to dementia. Series: "Alzheimer’s Disease" [Health and Medicine] [Science] [Show ID: 33600]

William Mobley, MD, PhD shares the latest research on preventing Alzheimer's disease in people with Down syndrome. He looks at the genetics and progression of both conditions and shares potential therapies to reduce APP expression that leads to dementia. Series: "Alzheimer’s Disease" [Health and Medicine] [Science] [Show ID: 33600]

2016 Kavli Prize recipient Carla Shatz from Stanford University presents a lively exploration of how understanding early stages of neural development may be leading to a pathway for developing treatments for Alzheimer's Disease. Series: "Alzheimer's Disease" [Health and Medicine] [Science] [Show ID: 31763]

2016 Kavli Prize recipient Carla Shatz from Stanford University presents a lively exploration of how understanding early stages of neural development may be leading to a pathway for developing treatments for Alzheimer's Disease. Series: "Alzheimer's Disease" [Health and Medicine] [Science] [Show ID: 31763]

2016 Kavli Prize recipient Carla Shatz from Stanford University presents a lively exploration of how understanding early stages of neural development may be leading to a pathway for developing treatments for Alzheimer's Disease. Series: "Alzheimer’s Disease" [Health and Medicine] [Science] [Show ID: 31763]

2016 Kavli Prize recipient Carla Shatz from Stanford University presents a lively exploration of how understanding early stages of neural development may be leading to a pathway for developing treatments for Alzheimer's Disease. Series: "Alzheimer’s Disease" [Health and Medicine] [Science] [Show ID: 31763]

2016 Kavli Prize recipient Carla Shatz from Stanford University presents a lively exploration of how understanding early stages of neural development may be leading to a pathway for developing treatments for Alzheimer's Disease. Series: "Alzheimer’s Disease" [Health and Medicine] [Science] [Show ID: 31763]

2016 Kavli Prize recipient Carla Shatz from Stanford University presents a lively exploration of how understanding early stages of neural development may be leading to a pathway for developing treatments for Alzheimer's Disease. Series: "Alzheimer’s Disease" [Health and Medicine] [Science] [Show ID: 31763]

Eric Siemers, MD, Distinguished Medical Fellow at Eli Lilly and Company joins William Mobley, MD, PhD to discuss clinical trails for Alzheimer's disease. He explains the trial design, results, and future implications of the EXPEDITION3 trial for people with with mild dementia due to Alzheimer's disease. Learn more about potential treatments in the clinical trials pipeline that may impact both the symptoms and pathologies of Alzheimer's disease. Series: "Alzheimer's Disease" [Health and Medicine] [Science] [Show ID: 31802]

Eric Siemers, MD, Distinguished Medical Fellow at Eli Lilly and Company joins William Mobley, MD, PhD to discuss clinical trails for Alzheimer's disease. He explains the trial design, results, and future implications of the EXPEDITION3 trial for people with with mild dementia due to Alzheimer's disease. Learn more about potential treatments in the clinical trials pipeline that may impact both the symptoms and pathologies of Alzheimer's disease. Series: "Alzheimer's Disease" [Health and Medicine] [Science] [Show ID: 31802]

As baby boomers age, an unprecedented number of people will be diagnosed with Alzheimer's disease. The economic and social impacts will be wide reaching from cost of treatment to the effect on caregivers. Maria Carrillo, PhD, Chief Science Officer, Alzheimer's Association joins Willliam Mobley. MD, PhD to discuss what can be done and how government, industry and the Alzheimer's Association are working together on larger scale trials and innovative projects. Series: "Alzheimer's Disease" [Health and Medicine] [Show ID: 31801]

As baby boomers age, an unprecedented number of people will be diagnosed with Alzheimer's disease. The economic and social impacts will be wide reaching from cost of treatment to the effect on caregivers. Maria Carrillo, PhD, Chief Science Officer, Alzheimer's Association joins Willliam Mobley. MD, PhD to discuss what can be done and how government, industry and the Alzheimer's Association are working together on larger scale trials and innovative projects. Series: "Alzheimer's Disease" [Health and Medicine] [Show ID: 31801]

Ara Khachaturian, PhD, chair and president of the National Biomedical Research Ethics Council joins WIilliam Mobley, MD, PhD to discuss the evolution of biomedical research in Alzheimer's disease and the ethical standards needed to maintain excellent patient care. From institutional review boards (IRB) to industry and academic partnerships, learn how we can support and maintain effective research infrastructure. Series: "Alzheimer's Disease" [Health and Medicine] [Show ID: 31770]

Ara Khachaturian, PhD, chair and president of the National Biomedical Research Ethics Council joins WIilliam Mobley, MD, PhD to discuss the evolution of biomedical research in Alzheimer's disease and the ethical standards needed to maintain excellent patient care. From institutional review boards (IRB) to industry and academic partnerships, learn how we can support and maintain effective research infrastructure. Series: "Alzheimer's Disease" [Health and Medicine] [Show ID: 31770]

Phyllis Ferrell, Vice President and Global Development Leader for Alzheimer's Disease at Eli Lilly and Company joins William Mobley, MD, PhD to talk about the goal set forth in the National Plan to Address Alzheimer's Disease to “prevent and effectively treat Alzheimer's disease by 2025.” Ferrell's shares her work to make Alzheimer's dementia preventable by finding ways to slow disease progression and advocating for early diagnosis. Series: "Alzheimer's Disease" [Health and Medicine] [Show ID: 31803]

Phyllis Ferrell, Vice President and Global Development Leader for Alzheimer's Disease at Eli Lilly and Company joins William Mobley, MD, PhD to talk about the goal set forth in the National Plan to Address Alzheimer's Disease to “prevent and effectively treat Alzheimer's disease by 2025.” Ferrell's shares her work to make Alzheimer's dementia preventable by finding ways to slow disease progression and advocating for early diagnosis. Series: "Alzheimer's Disease" [Health and Medicine] [Show ID: 31803]

For the past three decades the largest family in the world with a genetic form of Alzheimer's disease has been tracked. This extended family of some 5,000 individuals live in Antioquia, Colombia among a people who call themselves Paisa. Passing relentlessly through the generations with 100% penetrance is a mutation that causes early onset Alzheimer's disease in its carriers. Dr. Kenneth Kosik explains that the mutation in the Americas likely originated from a Spanish conquistador whose progeny are the members of the family we see today. Recently, interest in the family has grown because they are now participating in a clinical trial intended to delay the onset of the disease. Series: "Alzheimer's Disease" [Health and Medicine] [Science] [Show ID: 31481]

For the past three decades the largest family in the world with a genetic form of Alzheimer's disease has been tracked. This extended family of some 5,000 individuals live in Antioquia, Colombia among a people who call themselves Paisa. Passing relentlessly through the generations with 100% penetrance is a mutation that causes early onset Alzheimer's disease in its carriers. Dr. Kenneth Kosik explains that the mutation in the Americas likely originated from a Spanish conquistador whose progeny are the members of the family we see today. Recently, interest in the family has grown because they are now participating in a clinical trial intended to delay the onset of the disease. Series: "Alzheimer's Disease" [Health and Medicine] [Science] [Show ID: 31481]

How can communities better support the growing number of people affected by Alzheimer's disease? Mary Ball, president and CEO of the Alzheimer's Association, San Diego and Imperial Counties Chapter joins William Mobley, MD, PhD to discuss how her organization is trying to make a difference through information, support, and partnerships with local government. Series: "Alzheimer's Disease" [Health and Medicine] [Science] [Show ID: 28724]

How can communities better support the growing number of people affected by Alzheimer's disease? Mary Ball, president and CEO of the Alzheimer's Association, San Diego and Imperial Counties Chapter joins William Mobley, MD, PhD to discuss how her organization is trying to make a difference through information, support, and partnerships with local government. Series: "Alzheimer's Disease" [Health and Medicine] [Science] [Show ID: 28724]

What insights into Alzheimer's disease can cutting edge imaging techniques reveal? James Brewer, MD, PhD joins William Mobley, MD, PhD to discuss how this unique wiindow into the brain can be used to study the progression of the disease as well as help test new therapies. Series: "Alzheimer's Disease" [Health and Medicine] [Science] [Show ID: 28836]

How can we create more effective drugs for Alzheimer's disease? Michael Jackson, PhD joins William Mobley, MD, PhD to discuss the process of turning an idea into a drug. Creating connectivity between basic scientists, pharmaceutical companies, and the physicians on the front lines is a critical step as is embracing new ideas that may lead us to new therapeutic options. Series: "Alzheimer's Disease" [Health and Medicine] [Science] [Show ID: 28717]